Načítá se...
Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed...
Uloženo v:
| Vydáno v: | J Immunother Cancer |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7387312/ https://ncbi.nlm.nih.gov/pubmed/32699182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000952 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|